ASMALLWORLD AG (SWX: ASWN): Hansainvest erhöht Anteil an der ASMALLWORLD AG auf über 10%
» Report
Einige Inhalte dieser Seite sind nur für Abonnenten sichtbar.
Anmelden oder
Jetzt abonnieren!
Archiv: Alle Kategorien
Matthias Huenerwadel wird CEO der Zehnder Group
» Report
Significant shareholders - Significant shareholdings in companies whose equity securities are listed on SIX Swiss Exchange.
» SIX
Bedeutende Aktionäre - Bedeutende Beteiligungen an Gesellschaften, deren Beteiligungspapiere an SIX Swiss Exchange kotiert sind.
» SIX
Roche announces global availability of blood-based genomic profiling test, FoundationOne Liquid
» Report
HBM Healthcare Investments: Erfolgreicher Börsengang von Y-mAbs Therapeutics erhöht Inneren Wert je HBM-Aktie um CHF 4.82 (+2.7%)
» Report
SGS Implements Renovo™ Program in Ghana
» Report
BIS Quarterly Review: Divergences widen in markets
» Report
BIS Quarterly Review: Regulating cryptocurrencies: assessing market reactions
» B.I.S.
Swiss Re: Agostino Galvagni has decided to step down, Andreas Berger will succeed him as CEO Corporate Solutions and member of the Group Executive Committee
» Report
Aus dem Zentrum Malley wird die Vaudoise Aréna
» Report
Novartis to file for new Lucentis® (ranibizumab) indication in retinopathy of prematurity (ROP), a rare disease in premature infants that often leads to blindness
» Report
New analysis of Novartis Phase III brolucizumab (RTH258) data reinforces superior reduction of retinal fluid, a key marker of disease activity in nAMD
» Report
STOXX Changes Composition Of Blue-Chip Indices
» Report
STOXX Changes Composition Of Benchmark Indices
» Report
ein schönes Wochenende, have a great weekend!
Glencore : Glencore announces the final price of convertible bonds
» Report
Roche: CHMP recommends EU approval for subcutaneous formulation of RoActemra for use in active systemic juvenile idiopathic arthritis (sJIA), a rare form of juvenile arthritis
» Report
Julius Bär Warrants - New Issues
» Report
Roche announces CHMP recommendation for EU approval of Venclyxto plus MabThera for people with previously treated chronic lymphocytic leukaemia
» Report
